Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harpoon Therapeutics Inc (HARP)

Harpoon Therapeutics Inc (HARP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

Investors are still excited about obesity treatments and weight-management drugs.

NVO : 36.04 (-0.99%)
HARP : 23.01 (+0.09%)
MRK : 119.63 (+0.59%)
LLY : 878.24 (-2.09%)
This 1 Bullish Move by Merck Could Drive Growth for Years to Come

It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.

HARP : 23.01 (+0.09%)
MRK : 119.63 (+0.59%)
AMGN : 348.77 (-1.24%)
Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024

Stocks that traded heavily or had substantial price changes on Monday: Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise

ALK : 36.16 (-7.16%)
ANSS : 374.30 (-4.69%)
HARP : 23.01 (+0.09%)
MKKGY : 24.0400 (-1.88%)
BA : 190.52 (-1.98%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Big Tech Earnings

December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while...

GOOGL : 274.34 (-2.34%)
CVX : 211.15 (+1.62%)
MRK : 119.63 (+0.59%)
NQZ23 : 16,530.23s (-0.07%)
MSFT : 356.77 (-2.51%)
KNX : 55.55 (+0.07%)
MA : 484.24 (-3.30%)
V : 295.52 (-3.28%)
HARP : 23.01 (+0.09%)
WBA : 11.98 (+0.50%)
PINS : 17.76 (-1.11%)
ESZ23 : 4,694.27s (-0.58%)
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma

Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development

HARP : 23.01 (+0.09%)
Pre-Market Brief: Stocks Mixed As Investors Await Inflation Data, Fed meeting

December S&P 500 futures (ESZ22) are trending up +0.26% this morning after three major US benchmark indices closed lower on Friday, notching their biggest weekly drop in more than a month, as hotter-than-anticipated...

ULTA : 510.34 (-2.17%)
HARP : 23.01 (+0.09%)
HZNP : 116.30 (+0.04%)
RH : 130.85 (-0.89%)
GPC : 105.02 (-0.25%)
AMGN : 348.77 (-1.24%)
LI : 17.46 (-0.68%)
ESZ22 : 3,871.47s (-0.66%)
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting ...

HARP : 23.01 (+0.09%)
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company...

HARP : 23.01 (+0.09%)
Harpoon Therapeutics Expands Leadership Team

Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 ...

HARP : 23.01 (+0.09%)
Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Clinically active and well tolerated in patients with solid tumorsFavorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release...

HARP : 23.01 (+0.09%)

Barchart Exclusives

Everyone Is Talking About Volatility. That’s Not The Story.
Volatility isn’t the problem. The market is repricing flawed expectations, fragile ownership, and a structural shift investors haven’t caught up to yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.